奥扎格雷钠与依达拉奉联合治疗急性脑梗死（附48例疗效观察）

目的：观察依达拉奉联合奥扎格雷钠治疗急性脑梗死（AC I）的临床疗效。方法：将发病48 h内的AC I患者93例,随机分成治疗组（48例）和对照组（45例）。治疗组给予奥扎格雷钠80 mg＋生理盐水250 mL静脉滴注,2次/d,同时给予依达拉奉30 mg加入生理盐水100 mL静脉滴注,2次/d,连用14 d;对照组仅用同剂量、同疗程的奥扎格雷钠,共14 d。两组患者治疗前及治疗后21 d时均进行临床神经功能缺损程度评分及临床疗效评定。结果：治疗组总有效率95.8%,对照组总有效率73.3%,差异具有显著性（P〈0.05）。治疗组治疗后神经功能缺损程度评分较对照组显著改善（P〈0.05）,且无明显不良反应。结论：依达拉奉联合奥扎格雷钠治疗AC I患者疗效及安全性均较好。

The efficacy of edaravone sodium combined with ozagrel in patients with acute cerebralinfarction

Objective：To observate the efficacy of Ozagrel sodium combined with Edaravone in patients with acute cerebral infarction（ACI）.Methods：93 cases of acute cerebral infarction（ACI）,enrolled within 48h of onset and completed this study,were randomly divided into the treatment group（48cases）and control group（45 cases）.The treatment group was allocated Ozagrel sodium 80mg,Bid,for 14 days and Edaravone 30mg,Bid,for 14 d.And control group was only allocated Ozagrel sodium 80mg,Bid,for 14 d.The clinical effect and chnese scale of clinical neurologic deficit evaluation were used in the two groups before treatment and after. Results： The efficacy rate of treatment group were higher than that of control group （95.8%, 73.3%, P 〈 0.05 ）, compared with control group, neurologic impairment was more improved after treatment （ P 〈 0. 05 ）, and there was no obvious adverse effect in treatment group. Conclusions ： Edaravone combined with Ozagrel sodium is a effective and safe therapy for the ACI patients.